Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial
Authors
Keywords
-
Journal
Lancet Rheumatology
Volume 4, Issue 8, Pages e546-e555
Publisher
Elsevier BV
Online
2022-06-29
DOI
10.1016/s2665-9913(22)00131-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Predictors of Rituximab Effect on Modified Rodnan Skin Score in Systemic Sclerosis: a machine learning analysis of the DESIRES trial
- (2022) Satoshi Ebata et al. RHEUMATOLOGY
- Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis
- (2021) Sasimon Borrirukwisitsak et al. CLINICAL RHEUMATOLOGY
- Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis Associated Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Randomized, Placebo-controlled Trial
- (2021) Roham T Zamanian et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease
- (2021) Joanna Tieu et al. Frontiers in Immunology
- Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial
- (2021) Satoshi Ebata et al. Lancet Rheumatology
- Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis–Interstitial Lung Disease: Open Label Extension of a Phase 3 Randomized Controlled Trial
- (2021) Dinesh Khanna et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Single-cell-level protein analysis revealing the roles of autoantigen-reactive B lymphocytes in autoimmune disease and the murine model
- (2021) Takemichi Fukasawa et al. eLife
- Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients
- (2021) L Boekel et al. Lancet Rheumatology
- Systemic sclerosis-associated interstitial lung disease
- (2020) Apostolos Perelas et al. Lancet Respiratory Medicine
- Emerging targets of disease-modifying therapy for systemic sclerosis
- (2019) Elizabeth R. Volkmann et al. Nature Reviews Rheumatology
- Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study
- (2019) Muriel Elhai et al. ANNALS OF THE RHEUMATIC DISEASES
- Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti‐topoisomerase I‐positive systemic sclerosis‐associated interstitial lung disease
- (2019) Satoshi Ebata et al. JOURNAL OF DERMATOLOGY
- OUP accepted manuscript
- (2018) RHEUMATOLOGY
- Systemic sclerosis
- (2017) Christopher P Denton et al. LANCET
- Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis
- (2015) Silvia L. Bosello et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Systemic sclerosis
- (2015) Yannick Allanore et al. Nature Reviews Disease Primers
- Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
- (2014) Suzana Jordan et al. ANNALS OF THE RHEUMATIC DISEASES
- 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
- (2013) Frank van den Hoogen et al. ANNALS OF THE RHEUMATIC DISEASES
- B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis
- (2009) Robert Lafyatis et al. ARTHRITIS AND RHEUMATISM
- Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study
- (2009) Dimitrios Daoussis et al. RHEUMATOLOGY
- Interstitial Lung Disease in Systemic Sclerosis
- (2008) Nicole S. L. Goh et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study
- (2008) V Smith et al. ANNALS OF THE RHEUMATIC DISEASES
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started